Pentoxifylline for Acute Alcoholic Hepatitis (AAH)

The goal of this study is to demonstrate the effectiveness of pentoxifylline compared to placebo in AAH while studying putative mechanisms that are plausible and testable. The main hypothesis is that pentoxifylline reduces the 90-day mortality of AAH...

Date First Received: September 13, 2005

Last Updated: September 22, 2008

Verified by: University of Wisconsin, Madison, September 2008

Clinical Trial Phase: Phase 3 | Start Date: March 2005

Overall Status: Completed

Brief Summary

Official Title: “A Pilot Study of Pentoxifylline-Therapy for Acute Alcoholic Hepatitis”

Condition Keyword(s):

Intervention(s):

The goal of this study is to demonstrate the effectiveness of pentoxifylline compared to placebo in AAH while studying putative mechanisms that are plausible and testable. The main hypothesis is that pentoxifylline reduces the 90-day mortality of AAH.

Study Type: Interventional

Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Single Group Assignment, Efficacy Study

Study Primary Completion Date: July 2008

Intervention(s) in this Clinical Trial

  • Drug: pentoxifylline

Outcome Measures for this Clinical Trial

Primary Measures

  • Survival at 90 days

Secondary Measures

  • Survival at 28 days; the effect of pentoxifylline on circulating tumor necrosis factor (TNF), oxidative stress and renal function

Criteria for Participation in this Clinical Trial

Inclusion Criteria:

  • Inpatient with acute alcoholic hepatitis
  • Model for End-Stage Liver Disease (MELD) of 15 or greater
  • Recent alcohol abuse

Exclusion Criteria:

  • Recent infection
  • Other life threatening disease
  • Severe coagulopathy
  • Another non-alcoholic cause of liver disease

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: 18 Years

Maximum Age for this Clinical Trial: N/A

Are Healthy Volunteers Accepted for this Clinical Trial?: No

Clinical Trial Sponsor Information

Lead Sponsor: University of Wisconsin, Madison

Overall Clinical Trial Officials and Contacts

Michael R Lucey, MD Principal Investigator University of Wisconsin, Madison  

Additional Information

Information obtained from ClinicalTrials.gov on October 06, 2008

Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00205049

Study ID Number: M-2004-0388

ClinicalTrials.gov Identifier: NCT00205049

Health Authority: United States: Institutional Review Board

Clinical Trials Authorship and Review

Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.